Skip to main content

Wagner Heidi L's Form 4 filing

Wave Life Sciences, Inc.WVE · filed Aug 13, 2026

Accession no.
0001193125-26-349963
Filed
Aug 13, 2026, 9:00 PM ET
Trade date
Aug 11, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $42.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Wagner Heidi LCIK 0001655029Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 11, 2026Common StockMOption exerciseAcquired+7,000$5.97+$41,79051,930Direct
Aug 11, 2026Common StockSSaleDisposed−7,000$6.01−$42,07044,930Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 11, 2026Ordinary SharesMOption exerciseDisposed−7,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore ("Wave-Singapore"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the "Redomiciliation"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders. Exhibit 24.1 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)